These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 19927040)
1. A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months. Díez-Domingo J; Cantarino MV; Torrentí JM; Sansano MI; Rosich AJ; Merino AH; de Miguel AG; González JB; Marcos MD; Pediatr Infect Dis J; 2010 Feb; 29(2):148-52. PubMed ID: 19927040 [TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age. Tejedor JC; Moro M; Merino JM; Gómez-Campderá JA; García-del-Rio M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Ruiz-Contreras J; Martin-Ancel A; Roca J; Boceta R; García-Corbeira P; Maechler G; Boutriau D; Pediatr Infect Dis J; 2008 Jul; 27(7):579-88. PubMed ID: 18536619 [TBL] [Abstract][Full Text] [Related]
3. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study. Vesikari T; Forstén A; Desole MG; Ferrera G; Caubet M; Mesaros N; Boutriau D Pediatr Infect Dis J; 2013 May; 32(5):521-9. PubMed ID: 23190785 [TBL] [Abstract][Full Text] [Related]
4. Five-year antibody persistence and safety following a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine. Tejedor JC; Merino JM; Moro M; Navarro ML; Espín J; Omeñaca F; García-Sicilia J; Moreno-Pérez D; Ruiz-Contreras J; Centeno F; Barrio F; Cabanillas L; Muro M; Esporrin C; De Torres MJ; Caubet M; Boutriau D; Miller JM; Mesaros N Pediatr Infect Dis J; 2012 Oct; 31(10):1074-7. PubMed ID: 22828645 [TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine. Tejedor JC; Moro M; Ruiz-Contreras J; Castro J; Gómez-Campderá JA; Navarro ML; Merino JM; Martín-Ancel A; Roca J; García-del-Río M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Boceta R; García-Corbeira P; Jacquet JM; Collard A; Schuerman L; Pediatr Infect Dis J; 2006 Aug; 25(8):713-20. PubMed ID: 16874171 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine. Schmitt HJ; Maechler G; Habermehl P; Knuf M; Saenger R; Begg N; Boutriau D Clin Vaccine Immunol; 2007 Apr; 14(4):426-34. PubMed ID: 17287313 [TBL] [Abstract][Full Text] [Related]
7. Persistence of antibody response following a booster dose of Hib-MenC-TT glycoconjugate vaccine to five years: a follow-up study. Khatami A; Snape MD; Wysocki J; John TM; Westcar S; Mesaros N; Peddiraju K; Boutriau D; Yu LM; Pollard AJ Pediatr Infect Dis J; 2012 Oct; 31(10):1069-73. PubMed ID: 22673139 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial. Pace D; Khatami A; McKenna J; Campbell D; Attard-Montalto S; Birks J; Voysey M; White C; Finn A; Macloed E; Faust SN; Kent AL; Heath PT; Borrow R; Snape MD; Pollard AJ BMJ; 2015 Apr; 350():h1554. PubMed ID: 25832102 [TBL] [Abstract][Full Text] [Related]
9. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12-18 months of age. Habermehl P; Leroux-Roels G; Sänger R; Mächler G; Boutriau D Hum Vaccin; 2010 Aug; 6(8):640-51. PubMed ID: 20697200 [TBL] [Abstract][Full Text] [Related]
10. Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy. Pace D; Khatami A; Attard-Montalto S; Voysey M; Finn A; Faust SN; Heath PT; Borrow R; Snape MD; Pollard AJ Vaccine; 2016 Dec; 34(50):6350-6357. PubMed ID: 28029540 [TBL] [Abstract][Full Text] [Related]
11. A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial. Pace D; Snape M; Westcar S; Oluwalana C; Yu LM; Begg N; Wysocki J; Czajka H; Maechler G; Boutriau D; Pollard AJ Arch Dis Child; 2008 Nov; 93(11):963-70. PubMed ID: 18463125 [TBL] [Abstract][Full Text] [Related]
12. Randomized Trial to Compare the Immunogenicity and Safety of a CRM or TT Conjugated Quadrivalent Meningococcal Vaccine in Teenagers who Received a CRM or TT Conjugated Serogroup C Vaccine at Preschool Age. Ishola DA; Andrews N; Waight P; Yung CF; Southern J; Bai X; Findlow H; Matheson M; England A; Hallis B; Findlow J; Borrow R; Miller E Pediatr Infect Dis J; 2015 Aug; 34(8):865-74. PubMed ID: 26075813 [TBL] [Abstract][Full Text] [Related]
13. Combined Haemophilus Influenzae type B-Neisseria meningitidis serogroup C vaccine is immunogenic and well tolerated in preterm infants when coadministered with other routinely recommended vaccines. Omeñaca F; Arístegui J; Tejedor JC; Moreno-Perez D; Ruiz-Contreras J; Merino JM; Muro Brussi M; Sánchez-Tamayo T; Castro Fernandez J; Cabanillas L; Peddiraju K; Mesaros N; Miller JM Pediatr Infect Dis J; 2011 Nov; 30(11):e216-24. PubMed ID: 21747321 [TBL] [Abstract][Full Text] [Related]
14. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants. Marchant CD; Miller JM; Marshall GS; Blatter M; Aris E; Friedland LR; Boutriau D; Pediatr Infect Dis J; 2010 Jan; 29(1):48-52. PubMed ID: 20035207 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and reactogenicity of primary immunization with a novel combined Haemophilus influenzae Type b and Neisseria meningitidis Serogroup C-tetanus toxoid conjugate vaccine coadministered with a Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated poliovirus vaccine at 2, 4 and 6 months. Tejedor JC; Moro M; Ruiz-Contreras J; Castro J; Gómez-Campderá JA; Navarro ML; Merino JM; Martín-Ancel A; Roca J; García-Del-Rí M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Boceta R; García-Corbeira P; Collard A; Boutriau D; Schuerman L; Jacquet JM; Pediatr Infect Dis J; 2007 Jan; 26(1):1-7. PubMed ID: 17195697 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines. Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450 [TBL] [Abstract][Full Text] [Related]
17. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components. Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067 [TBL] [Abstract][Full Text] [Related]
18. Concomitant administration of a fully liquid ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal ACWY conjugate vaccine in toddlers. Vesikari T; Borrow R; Da Costa X; Thomas S; Eymin C; Boisnard F; Lockhart S Vaccine; 2018 Dec; 36(52):8019-8027. PubMed ID: 30471953 [TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers. Nolan T; Booy R; Marshall HS; Richmond P; Nissen M; Ziegler JB; Baine Y; Traskine M; Jastorff A; Van der Wielen M Pediatr Infect Dis J; 2019 Jun; 38(6):643-650. PubMed ID: 31116180 [TBL] [Abstract][Full Text] [Related]
20. A new combination haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants. Pace D; Snape M; Westcar S; Hamaluba M; Yu LM; Begg N; Wysocki J; Czajka H; Maechler G; Boutriau D; Pollard AJ Pediatr Infect Dis J; 2007 Nov; 26(11):1057-9. PubMed ID: 17984816 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]